Page 137 - HIV/AIDS Guidelines

6. Gandhi M, Aweeka F, Greenblatt RM, Blaschke TF. Sex differences in pharmacokinetics and pharmacodynamics. Annu
Rev Pharmacol Toxicol. 2004;44:499-523.

7. Floridia M, Giuliano M, Palmisano L, Vella S. Gender differences in the treatment of HIV infection. Pharmacol Res.
Sep-Oct 2008;58(3-4):173-182.

8. Ofotokun I, Chuck SK, Hitti JE. Antiretroviral pharmacokinetic profile: a review of sex differences. Gend Med. Jun
2007;4(2):106-119.

9. Baylor MS, Johann-Liang R. Hepatotoxicity associated with nevirapine use. J Acquir Immune Defic Syndr. Apr 15
2004;35(5):538-539.

10. Wit FW, Kesselring AM, Gras L, et al. Discontinuation of nevirapine because of hypersensitivity reactions in patients
with prior treatment experience, compared with treatment-naive patients: the ATHENA cohort study. Clin Infect Dis. Mar
15 2008;46(6):933-940.

11. Dieterich DT, Robinson PA, Love J, Stern JO. Drug-induced liver injury associated with the use of nonnucleoside
reverse-transcriptase inhibitors. Clin Infect Dis. Mar 1 2004;38(Suppl 2):S80-89.

12. Leith J, Piliero P, Storfer S, Mayers D, Hinzmann R. Appropriate use of nevirapine for long-term therapy. J Infect Dis.
Aug 1 2005;192(3):545-546; author reply 546.
13. Lactic Acidosis International Study Group LAISG. Risk factors for lactic acidosis and severe hyperlactataemia in HIV-1-
infected adults exposed to antiretroviral therapy. AIDS. Nov 30 2007;21(18):2455-2464.
14. Thiebaut R, Dequae-Merchadou L, Ekouevi DK, et al. Incidence and risk factors of severe hypertriglyceridaemia in the
era of highly active antiretroviral therapy: the Aquitaine Cohort, France, 1996-99. HIV Med. Apr 2001;2(2):84-88.
15. Galli M, Veglia F, Angarano G, et al. Gender differences in antiretroviral drug-related adipose tissue alterations. Women
are at higher risk than men and develop particular lipodystrophy patterns. J Acquir Immune Defic Syndr. Sep 1
2003;34(1):58-61.
16. Yin M, Dobkin J, Brudney K, et al. Bone mass and mineral metabolism in HIV+ postmenopausal women. Osteoporos
Int. Nov 2005;16(11):1345-1352.
17. Brown TT, Qaqish RB. Response to Berg et al. Antiretroviral therapy and the prevalence of osteopenia and osteoporosis:
a meta-analytic review. AIDS. Aug 20 2007;21(13):1830-1831.
18. Lampe MA, Smith DK, Anderson GJ, Edwards AE, Nesheim SR. Achieving safe conception in HIV-discordant couples:
the potential role of oral preexposure prophylaxis (PrEP) in the United States. Am J Obstet Gynecol. Jun
2011;204(6):488 e481-488.
19. Cohn SE, Park JG, Watts DH, et al. Depo-medroxyprogesterone in women on antiretroviral therapy: effective
contraception and lack of clinically significant interactions. Clin Pharmacol Ther. Feb 2007;81(2):222-227.
20. Nanda K, Amaral E, Hays M, Viscola MA, Mehta N, Bahamondes L. Pharmacokinetic interactions between depot
medroxyprogesterone acetate and combination antiretroviral therapy. Fertil Steril. Oct 2008;90(4):965-971.
21. Watts DH, Park JG, Cohn SE, et al. Safety and tolerability of depot medroxyprogesterone acetate among HIV-infected
women on antiretroviral therapy: ACTG A5093. Contraception. Feb 2008;77(2):84-90.
22. Leticee N, Viard JP, Yamgnane A, Karmochkine M, Benachi A. Contraceptive failure of etonogestrel implant in patients
treated with antiretrovirals including efavirenz. Contraception. Oct 27 2011.
23. Sevinsky H, Eley T, Persson A, et al. The effect of efavirenz on the pharmacokinetics of an oral contraceptive containing
ethinyl estradiol and norgestimate in healthy HIV-negative women. Antivir Ther. 2011;16(2):149-156.
24. Vogler MA, Patterson K, Kamemoto L, et al. Contraceptive efficacy of oral and transdermal hormones when co-
administered with protease inhibitors in HIV-1-infected women: pharmacokinetic results of ACTG trial A5188. J Acquir
Immune Defic Syndr. Dec 2010;55(4):473-482.

Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents I-21

Downloaded from http://aidsinfo.nih.gov/guidelines on 12/8/2012 EST.